{"name":"Tvardi Therapeutics","slug":"tvardi","ticker":"Private","exchange":"Private","domain":"tvarditherapeutics.com","description":"Tvardi Therapeutics is a private biopharmaceutical company focused on developing innovative oncology therapies, particularly in the area of targeted protein degradation. The company's pipeline includes several promising candidates, including its lead asset, Tvardi's PROTAC-based therapy. With a strong focus on oncology, Tvardi Therapeutics aims to bring novel treatments to patients in need. As a private company, Tvardi Therapeutics does not publicly disclose detailed financial information, but its pipeline and research efforts have garnered significant attention in the industry.","hq":"Houston, TX","founded":0,"employees":"","ceo":"Imad Shureiqi","sector":"Oncology / Targeted Protein Degradation","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (~$120M est. post-money)","metrics":{"revenue":5533000,"revenueGrowth":9.3,"grossMargin":0,"rdSpend":32805000,"netIncome":-70867000,"cash":43827000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"deal","headline":"Tvardi Therapeutics Secures $50M Series C Financing","summary":"Tvardi Therapeutics announced the completion of a $50 million Series C financing round, led by new investor, RA Capital Management, with participation from existing investors, including Sofinnova Partners and Morningside Ventures.","drugName":"","sentiment":"positive"},{"date":"2023-09-12","type":"trial","headline":"Tvardi Therapeutics Presents Positive Preclinical Data for PROTAC-Based Therapy at ESMO Congress","summary":"Tvardi Therapeutics presented preclinical data for its PROTAC-based therapy at the European Society for Medical Oncology (ESMO) Congress, highlighting the potential of its approach in targeting cancer-causing proteins.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPZ1ozd2RKaE02ZEtqTUhtUVBQeVhldE5XYVRlQVc1XzRZaUlpRVhCMFZPRi1sTHdXM0phNW5zcmRiTjRDRm1ZNU51YzN0QXFYR09GQnM5WE9uWkdNVFF4dEU3aXQxS0N3aENXbmwweVRVZTdTbS1JZlI2b0FWS1cyLTRac1RMSEZ5Mzg1LWlOZk1waVU?oc=5","date":"2024-12-18","type":"pipeline","source":"citybiz","summary":"Cara Therapeutics and Tvardi Therapeutics To Merge - citybiz","headline":"Cara Therapeutics and Tvardi Therapeutics To Merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOVGU4MkNUZ3lObFR1SHM0bVdfLW12Z0hpQnFSOGVaUkk4aXJxcUtMZlkycjBhRGJxbTFBbXlMN1NyYmtub0lwWWpIUl9ueGc3Y19BV1JlWnhrV1NjVXdvWU9yMDZGSTkzbXZVRV9SR0pyTVUyTnU0cmx6V0ozZnp4WUJtS3RMRmVvZWRKSDlscnVQNzhyTEFCOWpsWEZGX2JRdE9neWtYTDk4dHcxVWJ4dWNDWlBOU3poZ1MySGRQLXVZYnEyLWZ0c2c3WEgyaEJSYUdCSExpQVBybHRLSDJYQnRVZGk?oc=5","date":"2024-12-18","type":"deal","source":"GlobeNewswire","summary":"Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement - GlobeNewswire","headline":"Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNeDhTU1JhMFN5WEoybGxEY2UyYzd0NWF5eHp0ZVJXUVFEWU9jLWtyVDFTU2tCbHQ3VkRuY2Y3S1dTVDZSdG9BQUtRaHJFWHNuZEZMNmt3NmhtaXhrQ0hPeTZOeEhRYThRcDhYR202X24waEZwLURhNHl2UXJMcklleHZ1Y2lIaG1mbXl1RjV4am5Jd1V0MS0tYzRrc2o2LXRvdG1UTA?oc=5","date":"2024-12-18","type":"pipeline","source":"hartfordbusiness.com","summary":"Stamford’s Cara Therapeutics to merge with Houston biopharma firm - hartfordbusiness.com","headline":"Stamford’s Cara Therapeutics to merge with Houston biopharma firm","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Biospecifics Technologies Corporation","Proteostasis Therapeutics","Arvinas"],"therapeuticFocus":["Oncology","Targeted Protein Degradation"],"financials":{"source":"sec_edgar+yahoo","revenue":5533000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":5533000,"period":"2018-12-31"},{"value":5062000,"period":"2018-09-30"},{"value":2874000,"period":"2018-06-30"},{"value":911000,"period":"2017-12-31"},{"value":911000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":32805000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-70867000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":43827000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}